ChromaDex Corporation (CDXC): Price and Financial Metrics


ChromaDex Corporation (CDXC)

Today's Latest Price: $4.53 USD

0.01 (0.22%)

Updated Jul 2 4:00pm

Add CDXC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 68 in Chemicals

See all "A" rated Strong Buy stocks

CDXC Stock Summary

  • The ratio of debt to operating expenses for ChromaDex Corp is higher than it is for about merely 6.91% of US stocks.
  • With a year-over-year growth in debt of -32.27%, ChromaDex Corp's debt growth rate surpasses just 8.97% of about US stocks.
  • As for revenue growth, note that CDXC's revenue has grown 44.38% over the past 12 months; that beats the revenue growth of 88.53% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ChromaDex Corp, a group of peers worth examining would be PRPH, ADOM, USLM, BSTC, and TC.
  • CDXC's SEC filings can be seen here. And to visit ChromaDex Corp's official web site, go to www.chromadex.com.
CDXC Daily Price Range
CDXC 52-Week Price Range

CDXC Stock Price Chart Technical Analysis Charts


CDXC Price/Volume Stats

Current price $4.53 52-week high $5.80
Prev. close $4.52 52-week low $2.50
Day low $4.40 Volume 168,164
Day high $4.57 Avg. volume 409,265
50-day MA $4.74 Dividend yield N/A
200-day MA $3.97 Market Cap 278.50M

ChromaDex Corporation (CDXC) Company Bio


ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.


CDXC Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CDXC Latest Social Stream


Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about ChromaDex Corp that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen® to raise NAD+ levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on

Business Wire | June 30, 2020

ChromaDex (CDXC) Presents At Lytham Partners Virtual Investor Growth Conference - Slideshow

The following slide deck was published by ChromaDex Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | June 26, 2020

ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation

ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected quality management standard. This accreditation covers testing of the Company’s Tru Niagen® consumer products, its Niagen® ingredient, and phytochemical reference standards performed out of its quality control and R&D facility in Longmont, Colorado. The accreditation requires demonstration of full and continuous compliance with the most rigorous ISO quality standards, enabling ChromaDex to test and analyze its Tru Niagen® product, ingredients, and reference standards.

Yahoo | June 17, 2020

ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 2:00pm ET (11:00am PT). A webcast of the presentation will be posted under the investor relations section of ChromaDex’s website at www.chromadex.com, or can be accessed at https://www.webcaster4.com/Webcast/Page/2420/35343 or www.lythampartners.com/virtual. A replay

Business Wire | June 16, 2020

ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR)

ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the publication of results from preclinical research on cells and animal tissue infected with Coronavirus and a COVID-19 cadaver in the online scientific publishing website bioRxiv.org investigating the effect of viral infection on levels of NAD within the cell. The data showed a COVID-19 assault on the cells causes a greater than three-fold reduction in NAD and triggers the infected cells to specifically seek out nicotinamide riboside (NR) in an attempt to replenish NAD levels in the face of viral infection. While further research is underway, this early preclinical data suggests that increasing c...

Yahoo | June 16, 2020

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo -1.31%
3-mo 29.43%
6-mo 0.22%
1-year 4.14%
3-year 22.43%
5-year 26.89%
YTD 5.10%
2019 25.66%
2018 -41.67%
2017 77.64%
2016 -9.56%
2015 38.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9675 seconds.